Literature DB >> 25455503

Treatment goals for psoriasis: Should PASI 90 become the standard of care?

T Torres1, L Puig2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25455503     DOI： 10.1016/j.ad.2014.10.001

Source DB:  PubMed          Journal:  Actas Dermosifiliogr        ISSN： 0001-7310


× No keyword cloud information.
  7 in total

Review 1.  Selective Interleukin-23 p19 Inhibition: Another Game Changer in Psoriasis? Focus on Risankizumab.

Authors:  Tiago Torres
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature.

Authors:  I Belinchón; R Rivera; C Blanch; M Comellas; L Lizán
Journal:  Patient Prefer Adherence       Date:  2016-11-17       Impact factor: 2.711

3.  Analysis of treatment goal alignment between Japanese psoriasis patients and their paired treating physicians.

Authors:  Y Okubo; D Tsuruta; A C Tang; S Inoue; H Torisu-Itakura; T Hanada; M Ohtsuki
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-06       Impact factor: 6.166

Review 4.  Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.

Authors:  T Checchio; S Ahadieh; P Gupta; J Mandema; L Puig; R Wolk; H Valdez; H Tan; S Krishnaswami; A Tallman; M Kaur; K Ito
Journal:  Clin Pharmacol Ther       Date:  2017-06-21       Impact factor: 6.875

Review 5.  Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date.

Authors:  Álvaro Machado; Tiago Torres
Journal:  Psoriasis (Auckl)       Date:  2018-11-13

6.  A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management.

Authors:  L Grine; M de la Brassinne; P-D Ghislain; T Hillary; J Lambert; S Segaert; F Willaert; J Lambert
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-01-02       Impact factor: 6.166

7.  Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.

Authors:  Rani Soenen; Zhigang Wang; Lynda Grine; Erwin Dreesen; Lisa Schots; Els Brouwers; Paul Declerck; Debby Thomas; Jo Lambert
Journal:  Clin Exp Dermatol       Date:  2022-04-25       Impact factor: 4.481
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.